Why New Treatments for Schizophrenia Should Be on Your Radar

Background

Program Objectives

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Monitoring Drug Levels in Patients With Schizophrenia

The Importance of Monitoring Drug Levels

Poor Treatment Response in Schizophrenia

Rates of Subtherapeutic Drug Levels Are High

Effects of Drug Metabolism

Clinical Considerations for Plasma Drug Level Testing

Urine Drug Level Testing

Take-Home Messages

Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia

Topics for Discussion

A Brief Review of Biostatistics

NNT With Aripiprazole Lauroxil vs Placebo for PANSS Reduction

NNH and AE Rates With Aripiprazole Lauroxil vs Placebo

Clinical Considerations for Use of LAI Antipsychotics

Questions to Guide LAI Selection

Distinguishing Features of Available LAI Antipsychotics

Scientific Advances in the Biology of Schizophrenia: Focus on Mitochondrial Dysfunction

Topics for Discussion

Clinical Effects of Immune Dysregulation in Schizophrenia

A Brief Review of Mitochondria Action

Broad Effects of Mitochondrial Dysfunction

Looking Ahead: Targeting Mitochondria Therapeutically

Conclusions

New and Emerging Treatments for Schizophrenia: Part I

Relapse and Plasma Drug Levels After Discontinuation of Cariprazine

Relapse and Plasma Drug Levels After Discontinuation of Cariprazine: Results

Effect of Drug Half-Life on Relapse After Discontinuing Cariprazine

Effect of BI 409306 on PANSS: Phase 2 Trial

Effect of BI 409306 on PANSS: Results

Take-Home Messages

New and Emerging Treatments for Schizophrenia: Part II

Lumateperone: MOA

Lumateperone: Summary of Three Phase 3 Trials

Lumateperone Open-Label Switching Study: Design

Lumateperone Open-Label Switching Study: Safety

Lumateperone: Somnolence

Lumateperone Open-Label Switching Study: Efficacy

Take-Home Messages

Abbreviations

Abbreviations (cont)